



2024

1. Thompson KM, Badizadegan K. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs). Under Review.
2. Badizadegan ND, Wassalik SGF, Estivariz C, Wiesen E, Burns CC, Bolu O, Thompson KM. Intensification of population immunity prior to globally-coordinated cessation of bivalent oral poliovirus vaccine (bOPV). Under Review.
3. Thompson KM, Badizadegan K. Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020–2024. *Pathogens* 2024; in press.
4. Kalkowska DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, Zucker JR, Langdon-Embry M, Thompson KM. Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. *Expert Rev Vaccines* 2024; 23(1): 186-95. doi:10.1080/14760584.2023.2299401. <https://www.ncbi.nlm.nih.gov/pubmed/38164695>. Epub: 20240104.
5. Kalkowska DA, Wassilik SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. *Risk Anal* 2024; 44(2): 366-78. doi:10.1111/risa.14158. <https://www.ncbi.nlm.nih.gov/pubmed/37344934>. Epub: 20230621.
6. Kalkowska DA, Wiesen E, Wassilik SGF, Burns CC, Pallansch MA, Badizadegan K, Thompson KM. Worst-case scenarios: Modeling uncontrolled type 2 polio transmission. *Risk Anal* 2024; 44(2): 379-89. doi:10.1111/risa.14159. <https://www.ncbi.nlm.nih.gov/pubmed/37344376>. Epub: 20230621.
7. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. *Lancet* 2024. doi:10.1016/S0140-6736(24)00850-X. <https://www.ncbi.nlm.nih.gov/pubmed/38705159>. Epub: 20240502.
8. Thompson KM. Excess vaccine-preventable disease mortality due to COVID-19. *Lancet Glob Health* 2024; 12(4): e531-e2. doi:10.1016/S2214-109X(24)00046-9. [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(24\)00046-9/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00046-9/fulltext). Epub: April 2024.
9. Thompson KM, Kalkowska DA, Kidd SE, Burns CC, Badizadegan K. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. *Vaccine* 2024; 42(4): 819-27. doi:10.1016/j.vaccine.2023.12.081. <https://www.ncbi.nlm.nih.gov/pubmed/38218668>. Epub: 20240112.

2023

10. Thompson KM, Kalkowska DA, Routh JA, Brenner IR, Rosenberg ES, Zucker JR, Langdon-Embry M, Sugerman DE, Burns CC, Badizadegan K. Modeling poliovirus transmission and responses in New York State. *J Infect Dis* 2023; doi:10.1093/infdis/jjad355. <https://www.ncbi.nlm.nih.gov/pubmed/37596838>. Epub: 20230819.
11. Thompson KM, Kalkowska DA, Badizadegan K. Oral polio vaccine stockpile modeling: insights from recent experience. *Expert Rev Vaccines* 2023; 22(1): 813-25. doi:10.1080/14760584.2023.2263096. <https://www.ncbi.nlm.nih.gov/pubmed/37747090>. Epub: 20230929.
12. Thompson KM. Polio endgame complexity: updating expectations for nOPV2. *Lancet Infect Dis* 2023. doi:10.1016/S1473-3099(23)00133-0. <https://www.ncbi.nlm.nih.gov/pubmed/37178705>. Epub: 20230510.
13. Thompson KM, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. *Front Public Health*



- Health* 2023; 11. doi:10.3389/fpubh.2023.1098419.
<https://www.frontiersin.org/articles/10.3389/fpubh.2023.1098419>. Epub: 20230324.
14. Thompson KM, Luring AS, Pollard AJ, Andino R, Bandyopadhyay AS, Berkley S, Bhutta ZA, Routh J, Benn CS. Polio eradication: Addressing the hurdles on the last mile. *Cell* 2023; **186**(1): 1-4. doi:10.1016/j.cell.2022.12.021. <https://www.ncbi.nlm.nih.gov/pubmed/36608647>. Epub: 20230105.
15. Kalkowska DA, Wassilak SGF, Wiesen E, Estivariz CF, Burns CC, Badizadegan K, Thompson KM. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation [version 1; peer review: 1 approved]. *Gates Open Res* 2023. <https://gatesopenresearch.org/articles/7-55>. Epub: 20230417.

2022

16. Thompson KM. Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. *Lancet Glob Health* 2022; 10(12): e1697-e8. doi:10.1016/S2214-109X(22)00452-1. <https://www.ncbi.nlm.nih.gov/pubmed/36400075>
[https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X\(22\)00452-1.pdf](https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(22)00452-1.pdf).
17. Kalkowska DA, Wassilak SGF, Pallansch MA, Burns CC, Wiesen E, Durry E, Badizadegan K, Thompson KM. Outbreak response strategies with type 2-containing oral poliovirus vaccines. *Vaccine* 2023. 41 Suppl 1: A142-A52. doi:10.1016/j.vaccine.2022.10.060. <https://www.ncbi.nlm.nih.gov/pubmed/36402659>. Epub 20221116.
18. Thompson KM, Kalkowska DA, Badizadegan K. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. *Expert Rev Vaccines* 2022. doi:10.1080/14760584.2022.2128108. <https://www.ncbi.nlm.nih.gov/pubmed/36154436>. Epub20220926.
19. Badizadegan K, Kalkowska DA, Thompson KM. Polio by the Numbers – A Global Perspective. *J Infect Dis* 2022. <https://doi.org/10.1093/infdis/jiac130>. Epub 20220414.
20. Kalkowska DA, Badizadegan K, Thompson KM. Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Anal.* 2002. doi:10.1111/risa.13982. <https://pubmed.ncbi.nlm.nih.gov/35739067/>. Epub 20220623.
21. Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. *Risk Anal.* 2022. doi:10.1111/risa.13983. <https://pubmed.ncbi.nlm.nih.gov/35739080/>. Epub 20220623.
22. Thompson K, Kalkowska D, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. *Gates Open Research* 2022; 6(5). doi:10.12688/gatesopenres.13524.1. <https://gatesopenresearch.org/articles/6-5/v1>. [version 1; peer review: 2 approved]
23. Thompson KM. Polio eradication: what kind of world do we want? *Lancet Infect Dis* 2022; 22(2): 161-3. doi:10.1016/S1473-3099(21)00458-8. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00458-8/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00458-8/fulltext). Epub 20211011.
24. Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. *Expert Rev Vaccines* 2022: 1-16. doi:10.1080/14760584.2022.2017287. <https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2017287>. Epub 20220112.

2021

25. Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Modeling poliovirus surveillance and immunization campaign quality monitoring costs for Pakistan and Afghanistan for 2019-2023. *Open*



- Forum Infect Dis* 2021. doi:10.1093/ofid/ofab264. <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab264/6282445>. Epub 2021/05/23.
26. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. *Vaccine* 2023. 41 Suppl 1:A136-A41. doi:10.1016/j.vaccine.2021.04.061. <https://www.sciencedirect.com/science/article/pii/S0264410X21005430>. Epub 2021/05/14.
 27. Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. *Vaccine* 2023. 41 Suppl 1: A12-A8. doi:10.1016/j.vaccine.2021.04.026. <https://www.sciencedirect.com/science/article/pii/S0264410X21004734>. Epub 2021/04/27.
 28. Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options. *J Infect Dis* 2021. doi:10.1093/infdis/jiab160. <https://www.ncbi.nlm.nih.gov/pubmed/33885734>. Epub 2021/04/23.
 29. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891888. <https://www.ncbi.nlm.nih.gov/pubmed/33624568>. Epub 2021/02/25.
 30. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891889. <https://www.ncbi.nlm.nih.gov/pubmed/33599178>. Epub 2021/02/19.
 31. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. *Risk Anal* 2021; 41(2): 364-75. doi:10.1111/risa.13664. <https://www.ncbi.nlm.nih.gov/pubmed/33590519>. Epub 2021/02/15.
 32. Thompson KM. Modeling and managing poliovirus risks: We are where we are.... *Risk Analysis* 2021; 41(2): 223-8. doi:10.1111/risa.13668. <https://pubmed.ncbi.nlm.nih.gov/33590520>. Epub 2021/2/5.
 33. Thompson KM. Poliovirus vaccine options: another step forward. *Lancet* 2021; 397(10268): 2-3. doi:10.1016/S0140-6736(20)32629-5. <https://www.ncbi.nlm.nih.gov/pubmed/33308426>. Epub 2020/12/15.
 34. Secondary Vaccine Effects Workshop Planning Committee. NIAID workshop on secondary vaccine effects. *Nat Immunol* 2021; **22**(11): 1363-6. doi:10.1038/s41590-021-01054-5. <https://www.ncbi.nlm.nih.gov/pubmed/34686866>. Epub: 2021/02/22.
 35. Thompson KM, Kalkowska DA, Badizadegan K. A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. *Risk Anal* 2021; 41(2): 376-86. doi:10.1111/risa.13614. <https://www.ncbi.nlm.nih.gov/pubmed/33084153>. Epub 2020/10/22.
 36. Thompson KM, Kalkowska DA, Badizadegan K. No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]. *Risk Anal* 2021; 41(2): 389-92. doi:10.1111/risa.13671. <https://www.ncbi.nlm.nih.gov/pubmed/33590518>. Epub 2021/02/17.
 37. Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication initiative. *Risk Analysis* 2021; 41(2): 393-406. doi:10.1111/risa.13665. <https://pubmed.ncbi.nlm.nih.gov/33590521>. Epub 2021/2/5.
 38. Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. *Risk Anal* 2021; 41(2): 349-63. doi:10.1111/risa.13557. <https://www.ncbi.nlm.nih.gov/pubmed/32645244>. Epub 2020/07/10.
 39. Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. *Risk Anal* 2021; 41(2): 229-47. doi:10.1111/risa.13484. <https://pubmed.ncbi.nlm.nih.gov/32339327>. Epub 2020/04/28.



40. Kalkowska DA, Thompson KM. expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. *Risk Anal* 2021; 41(2): 312-9. doi:10.1111/risa.13590. <https://pubmed.ncbi.nlm.nih.gov/32936466>. Epub 2020/09/17.
41. Kalkowska DA, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in Northeast Nigeria. *Risk Anal* 2021; 41(2): 303-11. doi:10.1111/risa.13486. <https://pubmed.ncbi.nlm.nih.gov/32348634>. Epub 2020/04/30.
42. Kalkowska DA, Thompson KM. Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan. *Risk Anal* 2021; 41(2): 266-72. doi:10.1111/risa.13471. <https://www.ncbi.nlm.nih.gov/pubmed/32144841>. Epub 2020/03/08.
43. Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Updated characterization of outbreak response strategies for 2019-2029: Impacts of using a novel type 2 oral poliovirus vaccine strain. *Risk Anal* 2021; 41(2): 329-48. doi:10.1111/risa.13622. <https://www.ncbi.nlm.nih.gov/pubmed/33174263>. Epub 2020/11/12.
44. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame. *Risk Anal* 2021; 41(2): 248-65. doi:10.1111/risa.13447. <https://www.ncbi.nlm.nih.gov/pubmed/31960533>. Epub 2020/01/22.
45. Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. *Risk Anal* 2021; 41(2): 320-8. doi:10.1111/risa.13555. <https://www.ncbi.nlm.nih.gov/pubmed/32632925>. Epub 2020/07/08.
46. Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM. Modeling poliovirus transmission in Borno and Yobe, Northeast Nigeria. *Risk Anal* 2021; 41(2): 289-302. doi:10.1111/risa.13485. <https://pubmed.ncbi.nlm.nih.gov/32348621>. Epub 2020/04/30.

2020

47. Ochalek J, Claxton K, Lomas J, Thompson KM. Valuing health outcomes: developing better defaults based on health opportunity costs. *Expert Rev Pharmacoecon Outcomes Res* 2020: 1-8. doi:10.1080/14737167.2020.1812387. <https://www.ncbi.nlm.nih.gov/pubmed/32954900>. Epub 2020/09/22.
48. Badizadegan K, Vanlandingham DM, Hampton W, Thompson KM. Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America. *BMC Health Serv Res* 2020; 20(1): 962. doi:10.1186/s12913-020-05815-0. <https://bmchealthservres.biomedcentral.com/track/pdf/10.1186/s12913-020-05815-0>. Epub 2020/10/22.
49. Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. *Expert Review of Vaccines* 2020: 1-25. doi:10.1080/14760584.2020.1791093. <https://doi.org/10.1080/14760584.2020.1791093>. Epub 2020/08/01.
50. Thompson KM, Orenstein WA, Hinman AR. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches. *Vaccine* 2020. doi:10.1016/j.vaccine.2020.04.044. <https://pubmed.ncbi.nlm.nih.gov/32339327/>. Epub 2020/04/30.
51. Badizadegan K, Goodson JL, Rota PA, Thompson KM. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. *Expert Rev Vaccines* 2020; 19(2): 175-94. doi:10.1080/14760584.2020.1732215. <https://www.ncbi.nlm.nih.gov/pubmed/32182145>. Epub 2020 Mar 17.
52. Thompson KM, Orenstein WA, Hinman AR. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019. *Vaccine* 2020. doi: 10.1016/j.vaccine.2020.01.042. <https://doi.org/10.1016/j.vaccine.2020.01.042>. Epub 2020 Jan 22.



53. Vanlandingham DM, Hampton W, Thompson KM, Badizadegan K. Modeling pathology workload and complexity to manage risks and improve patient quality and safety. *Risk Anal* 2020; 40(2): 421-34. doi:10.1111/risa.13393. <https://www.ncbi.nlm.nih.gov/pubmed/31476083>. Epub 2019 Sep 2.

2019

54. Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). *Expert Rev Vaccines* 2019; 18(7): 725-36. doi:10.1080/14760584.2019.1635463. <https://www.ncbi.nlm.nih.gov/pubmed/31248293>
55. Thompson KM. What will it take to end fatalities from measles? *Lancet Glob Health* 2019; 7(4): e394-e5. doi:10.1016/s2214-109x(19)30050-6. <https://www.ncbi.nlm.nih.gov/pubmed/30797736>
56. Thompson KM. Polio endgame options: will we have the vaccines needed? *Lancet* 2019; 394(10193): 99-100. doi:10.1016/S0140-6736(19)31294-2. <https://www.ncbi.nlm.nih.gov/pubmed/31174833>
57. Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excretors. *Epidemiol Infect* 2019; 147: e295. doi:10.1017/s095026881900181x. <https://www.ncbi.nlm.nih.gov/pubmed/31647050>
58. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation. *Risk Anal* 2019; 39(2): 414-25. doi:10.1111/risa.13193. <https://www.ncbi.nlm.nih.gov/pubmed/30239023>
59. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Anal* 2019; 39(2): 402-13. doi:10.1111/risa.13214. <https://www.ncbi.nlm.nih.gov/pubmed/30296340>
60. Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. *Risk Anal* 2019; 39(2): 389-401. doi:10.1111/risa.13194. <https://www.ncbi.nlm.nih.gov/pubmed/30239026>
61. Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM. Characterising the costs of the global polio laboratory network: a survey-based analysis. *BMJ Open* 2019; 9(1): e023290. doi:10.1136/bmjopen-2018-023290. <https://www.ncbi.nlm.nih.gov/pubmed/30670511>

2018

62. Tebbens RJD, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. *Future Virology* 2018; 13(9): 617-28. doi:10.2217/fvl-2018-0079. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2018-0079>
63. Ozawa S, Yemeke TT, Thompson KM. Systematic review of the incremental costs of interventions that increase immunization coverage. *Vaccine* 2018; 36(25): 3641-9. doi:10.1016/j.vaccine.2018.05.030. <https://www.ncbi.nlm.nih.gov/pubmed/29754699>
64. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Another look at silent circulation of poliovirus in small populations. *Infect Dis Model* 2018; 3: 107-17. doi:10.1016/j.idm.2018.06.001. <https://www.ncbi.nlm.nih.gov/pubmed/30839913>
65. Duintjer Tebbens RJ, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. *System Dynamics Review* 2018; 34(1-2): 78-120. doi:10.1002/sdr.1589. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.1589>
66. Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. *Expert Rev Vaccines* 2018; 17(8): 739-51. doi:10.1080/14760584.2018.1506333. <https://www.ncbi.nlm.nih.gov/pubmed/30056767>



67. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. *Risk Anal* 2018; 38(8): 1701-17. doi:10.1111/risa.12962. <https://www.ncbi.nlm.nih.gov/pubmed/29314143>
68. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. *BMC Infect Dis* 2018; 18(1): 165. doi:10.1186/s12879-018-3074-0. <https://www.ncbi.nlm.nih.gov/pubmed/29631539>

2017

69. Thompson KM, Tebbens RJD. How should we prepare for an outbreak of reintroduced live polioviruses? *Future Virology* 2017; 12(2): 41-4. doi:10.2217/fvl-2016-0131. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2016-0131>
70. Thompson KM, Duintjer Tebbens RJ. Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. *J Infect Dis* 2017; 216(suppl_1): S168-S75. doi:10.1093/infdis/jix128. <https://www.ncbi.nlm.nih.gov/pubmed/28838198>
71. Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. *J Infect Dis* 2017; 216(suppl_1): S176-S82. doi:10.1093/infdis/jix108. <https://www.ncbi.nlm.nih.gov/pubmed/28838194>
72. Thompson KM, Badizadegan ND. Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases. *Risk Anal* 2017; 37(6): 1109-31. doi:10.1111/risa.12831. <https://www.ncbi.nlm.nih.gov/pubmed/28561947>
73. Thompson KM. What will it take to end human suffering from measles? *Lancet Infect Dis* 2017; 17(10): 1013-4. doi:10.1016/s1473-3099(17)30451-6. <https://www.ncbi.nlm.nih.gov/pubmed/28807626>
74. Thompson KM. Modeling and managing the risks of measles and rubella: a global perspective part II. *Risk Anal* 2017; 37(6): 1041-51. doi:10.1111/risa.12823. <https://www.ncbi.nlm.nih.gov/pubmed/28471528>
75. Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. *Food Environ Virol* 2017; 9(4): 361-82. doi:10.1007/s12560-017-9314-4. <https://www.ncbi.nlm.nih.gov/pubmed/28687986>
76. Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. *Epidemiol Infect* 2017; 145(2): 217-26. doi:10.1017/S0950268816002302. <https://www.ncbi.nlm.nih.gov/pubmed/27760579>
77. Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. *MDM Policy Pract* 2017; 2(1): 2381468317697002. doi:10.1177/2381468317697002. <https://www.ncbi.nlm.nih.gov/pubmed/30288417>
78. Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. *Expert Rev Vaccines* 2017; 16(6): 577-86. doi:10.1080/14760584.2017.1322514. <https://www.ncbi.nlm.nih.gov/pubmed/28437234>
79. Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. *Vaccine* 2017; 35(31): 3823-33. doi:10.1016/j.vaccine.2017.05.090. <https://www.ncbi.nlm.nih.gov/pubmed/28606811>

2016



80. Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. *Risk Anal* 2016; 36(7): 1315-31. doi:10.1111/risa.12264. <https://www.ncbi.nlm.nih.gov/pubmed/25100307>
81. Thompson KM, Odahowski CL, Goodson JL, Reef SE, Perry RT. Synthesis of evidence to characterize national measles and rubella exposure and immunization histories. *Risk Anal* 2016; 36(7): 1427-58. doi:10.1111/risa.12454. <https://www.ncbi.nlm.nih.gov/pubmed/26249328>
82. Thompson KM, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. *Risk Anal* 2016; 36(7): 1297-314. doi:10.1111/risa.12331. <https://www.ncbi.nlm.nih.gov/pubmed/25545778>
83. Thompson KM, Odahowski CL. Systematic review of measles and rubella serology studies. *Risk Anal* 2016; 36(7): 1459-86. doi:10.1111/risa.12430. <https://www.ncbi.nlm.nih.gov/pubmed/26077609>
84. Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. *Risk Anal* 2016; 36(7): 1357-82. doi:10.1111/risa.12459. <https://www.ncbi.nlm.nih.gov/pubmed/26249331>
85. Thompson KM, Logan GE, Florida SRT. Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data. *Risk Anal* 2016; 36(7): 1418-26. doi:10.1111/risa.12424. <https://www.ncbi.nlm.nih.gov/pubmed/26033542>
86. Thompson KM, Kisjes KH. Modeling measles transmission in the North American Amish and options for outbreak response. *Risk Anal* 2016; 36(7): 1404-17. doi:10.1111/risa.12440. <https://www.ncbi.nlm.nih.gov/pubmed/26103154>
87. Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. *Risk Anal* 2016; 36(7): 1487-509. doi:10.1111/risa.12265. <https://www.ncbi.nlm.nih.gov/pubmed/25109229>
88. Thompson KM, Cochi SL. Modeling and managing the risks of measles and rubella: a global perspective, part I. *Risk Anal* 2016; 36(7): 1288-96. doi:10.1111/risa.12655. <https://www.ncbi.nlm.nih.gov/pubmed/27424287>
89. Thompson KM. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. *Risk Anal* 2016; 36(7): 1383-403. doi:10.1111/risa.12637. <https://www.ncbi.nlm.nih.gov/pubmed/27277138>
90. Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. *J Vaccines Vaccin* 2016; 7(5). doi:10.4172/2157-7560.1000340. <https://www.ncbi.nlm.nih.gov/pubmed/28690915>
91. Simons EA, Reef SE, Cooper LZ, Zimmerman L, Thompson KM. Systematic review of the manifestations of congenital rubella syndrome in infants and characterization of disability-adjusted life years (DALYs). *Risk Anal* 2016; 36(7): 1332-56. doi:10.1111/risa.12263. <https://www.ncbi.nlm.nih.gov/pubmed/25115193>
92. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. *Nat Rev Dis Primers* 2016; 2: 16049. doi:10.1038/nrdp.2016.49. <https://www.ncbi.nlm.nih.gov/pubmed/27411684>
93. Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management *J Vaccines Vaccin* 2016; 7(5): 1000339. doi:10.4172/2157-7560.1000339. <https://www.longdom.org/open-access/uncertainty-and-sensitivity-analysis-of-cost-assumptions-for-global-longtermpoliiovirus-risk-management-2157-7560-1000339.pdf>
94. Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. *Future Microbiol* 2016; 11: 1549-61. doi:10.2217/fmb-2016-0126. <https://www.ncbi.nlm.nih.gov/pubmed/27831742>
95. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. *BMC Infect Dis* 2016; 16: 137. doi:10.1186/s12879-016-1465-7. <https://www.ncbi.nlm.nih.gov/pubmed/27009272>
96. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. *BMC Infect Dis* 2016; 16: 231. doi:10.1186/s12879-016-1536-9. <https://www.ncbi.nlm.nih.gov/pubmed/27230071>



97. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. *BMC Infect Dis* 2016; 16: 237. doi:10.1186/s12879-016-1537-8. <https://www.ncbi.nlm.nih.gov/pubmed/27246198>

2015

98. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. *Vaccine* 2015; 33(13): 1568-77. doi:10.1016/j.vaccine.2015.02.013. <https://www.ncbi.nlm.nih.gov/pubmed/25701673>
99. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL. Polio eradicators use integrated analytical models to make better decisions. *INFORMS Journal on Applied Analytics* 2015; 45(1): 5-25. doi:10.1287/inte.2014.0769. <https://pubsonline.informs.org/doi/abs/10.1287/inte.2014.0769>
100. Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. *BMC Infect Dis* 2015; 15: 374. doi:10.1186/s12879-015-1113-7. <https://www.ncbi.nlm.nih.gov/pubmed/26381878>
101. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. *BMC Infect Dis* 2015; 15: 376. doi:10.1186/s12879-015-1116-4. <https://www.ncbi.nlm.nih.gov/pubmed/26382234>
102. Thompson KM. Good news for billions of children who will receive IPV. *Lancet Infect Dis* 2015; 15(10): 1120-2. doi:10.1016/S1473-3099(15)00099-7. <https://www.ncbi.nlm.nih.gov/pubmed/26289957>
103. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. *BMC Infect Dis* 2015; 15: 66. doi:10.1186/s12879-015-0791-5. <https://www.ncbi.nlm.nih.gov/pubmed/25886823>
104. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. *J Infect Dis* 2015; 211(11): 1800-12. doi:10.1093/infdis/jiu674. <https://www.ncbi.nlm.nih.gov/pubmed/25505296>
105. Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. *BMC Infect Dis* 2015; 15: 390. doi:10.1186/s12879-015-1114-6. <https://www.ncbi.nlm.nih.gov/pubmed/26404780>
106. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *PLoS One* 2015; 10(6): e0130123. doi:10.1371/journal.pone.0130123. <https://www.ncbi.nlm.nih.gov/pubmed/26068928>
107. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. *BMC Infect Dis* 2015; 15: 379. doi:10.1186/s12879-015-1115-5. <https://www.ncbi.nlm.nih.gov/pubmed/26382043>
108. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. *BMC Infect Dis* 2015; 15: 389. doi:10.1186/s12879-015-1112-8. <https://www.ncbi.nlm.nih.gov/pubmed/26404632>
109. Berera D, Thompson KM. Medical student knowledge, attitudes, and practices regarding immunization. *J Vaccines Vaccin* 2015; 6(1): 1000268. doi:10.4172/2157-7560.1000268. <https://www.longdom.org/open-access/medical-student-knowledge-attitudes-and-practices-regarding-immunization-2157-7560.1000268.pdf>

2014



110. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. *J Infect Dis* 2014; 210 Suppl 1: S475-84. doi:10.1093/infdis/jit845. <https://www.ncbi.nlm.nih.gov/pubmed/25316870>
111. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. *Expert Rev Vaccines* 2014; 13(2): 221-34. doi:10.1586/14760584.2014.864563. <https://www.ncbi.nlm.nih.gov/pubmed/24308581>
112. Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. *Lancet* 2014; 384(9953): 1480-2. doi:10.1016/S0140-6736(14)60983-1. <https://www.ncbi.nlm.nih.gov/pubmed/25018123>
113. Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. *J Infect Dis* 2014; 210 Suppl 1: S424-33. doi:10.1093/infdis/jit843. <https://www.ncbi.nlm.nih.gov/pubmed/25316864>
114. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. *J Infect Dis* 2014; 210 Suppl 1: S398-411. doi:10.1093/infdis/jit844. <https://www.ncbi.nlm.nih.gov/pubmed/25316861>
115. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *J Infect Dis* 2014; 210 Suppl 1: S412-23. doi:10.1093/infdis/jit834. <https://www.ncbi.nlm.nih.gov/pubmed/25316863>
116. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. *J Infect Dis* 2014; 210 Suppl 1: S485-97. doi:10.1093/infdis/jit838. <https://www.ncbi.nlm.nih.gov/pubmed/25316871>
117. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. *BMC Infect Dis* 2014; 14: 45. doi:10.1186/1471-2334-14-45. <https://www.ncbi.nlm.nih.gov/pubmed/24472313>

2013

118. Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL. Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention. *Vaccine* 2013; 31 Suppl 2: B149-56. doi:10.1016/j.vaccine.2012.11.091. <https://www.ncbi.nlm.nih.gov/pubmed/23598476>
119. Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. *Risk Anal* 2013; 33(4): 647-63. doi:10.1111/j.1539-6924.2012.01891.x. <https://www.ncbi.nlm.nih.gov/pubmed/22985171>
120. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. *Risk Anal* 2013; 33(4): 516-43. doi:10.1111/risa.12019. <https://www.ncbi.nlm.nih.gov/pubmed/23461599>
121. Thompson KM, Duintjer Tebbens RJ, Chagnat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC. Managing cholera as a preventable global threat. *J Vaccines Vaccin* 2013; 4(183): 1000183. doi:10.4172/2157-7560.1000183. <https://www.longdom.org/open-access/managing-cholera-as-a-preventable-global-threat-2157-7560.1000183.pdf>
122. Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. *Risk Anal* 2013; 33(4): 505-15. doi:10.1111/risa.12030. <https://www.ncbi.nlm.nih.gov/pubmed/23550939>
123. Hennelly KE, Mannix R, Nigrovic LE, Lee LK, Thompson KM, Monuteaux MC, Proctor M, Schutzman S. Pediatric traumatic brain injury and radiation risks: a clinical decision analysis. *J Pediatr* 2013; 162(2): 392-7. doi:10.1016/j.jpeds.2012.07.018. <https://www.ncbi.nlm.nih.gov/pubmed/22921827>



124. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal* 2013; 33(4): 680-702. doi:10.1111/risa.12022. <https://www.ncbi.nlm.nih.gov/pubmed/23470192>
125. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. *Risk Anal* 2013; 33(4): 703-49. doi:10.1111/risa.12044. <https://www.ncbi.nlm.nih.gov/pubmed/23521018>
126. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission. *Risk Anal* 2013; 33(4): 544-605. doi:10.1111/j.1539-6924.2012.01864.x. <https://www.ncbi.nlm.nih.gov/pubmed/22804479>
127. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. *Risk Anal* 2013; 33(4): 606-46. doi:10.1111/risa.12031. <https://www.ncbi.nlm.nih.gov/pubmed/23550968>

2012

128. Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. *Public Health Rep* 2012; 127(1): 23-37. doi:10.1177/003335491212700104. <https://www.ncbi.nlm.nih.gov/pubmed/22298920>
129. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. *Expert Rev Vaccines* 2012; 11(4): 449-59. doi:10.1586/erv.11.195. <https://www.ncbi.nlm.nih.gov/pubmed/22551030>
130. Thompson KM, Duintjer Tebbens RJ. Development of investment cases for globally-coordinated management of infectious diseases. *J Vaccines Vaccin* 2012; 3(8): 164. doi:10.4172/2157-7560.1000164. <https://www.longdom.org/open-access/development-of-investment-cases-for-globally-coordinated-management-of-infectious-diseases-2157-7560.1000164.pdf>
131. Thompson KM, Dabbagh A, Strebel PM, Perry R, Gacic-Dobo M, Cochi SL, Cairns L, Reef S. National and global options for managing the risks of measles and rubella. *J Vaccines Vaccin* 2012; 3: 165. doi:10.4172/2157-7560.1000165. <https://www.longdom.org/open-access/national-and-global-options-for-managing-the-risks-of-measles-and-rubella-2157-7560.1000165>
132. Thompson KM. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. *ICU Management* 2012; 12(4): 9-11.
133. Thompson KM. The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices. *Expert Rev Vaccines* 2012; 11(1): 5-7. doi:10.1586/erv.11.163. <https://www.ncbi.nlm.nih.gov/pubmed/22149700>
134. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. *Am J Epidemiol* 2012; 175(9): 936-49. doi:10.1093/aje/kwr399. <https://www.ncbi.nlm.nih.gov/pubmed/22459121>
135. Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM. Research priorities for global measles and rubella control and eradication. *Vaccine* 2012; 30(32): 4709-16. doi:10.1016/j.vaccine.2012.04.058. <https://www.ncbi.nlm.nih.gov/pubmed/22549089>
136. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics. *Epidemiol Infect* 2011; 139(6): 836-48. doi:10.1017/S0950268810001676. <https://www.ncbi.nlm.nih.gov/pubmed/20619075>



2007 - 2011

137. Badizadegan K, Thompson KM. Value of information in nonfocal colonic biopsies. *J Pediatr Gastroenterol Nutr* 2011; 53(6): 679-83. doi:10.1097/MPG.0b013e31822862d9.
<https://www.ncbi.nlm.nih.gov/pubmed/21681109>
138. Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. *Vaccine* 2010; 28(26): 4312-27. doi:10.1016/j.vaccine.2010.04.001.
<https://www.ncbi.nlm.nih.gov/pubmed/20430122>
139. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. *Vaccine* 2010; 29(2): 334-43. doi:10.1016/j.vaccine.2010.10.026. <https://www.ncbi.nlm.nih.gov/pubmed/21029809>
140. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. *Manag Sci* 2009; 55(4): 650-63. doi:10.1287/mnsc.1080.0965.
<https://pubsonline.informs.org/doi/10.1287/mnsc.1080.0965>
141. Thompson KM, Tebbens RJD. Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond. *System Dynamics Review* 2008; 24(4): 433-49. doi:10.1002/sdr.419.
<https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.419>
142. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. *Am J Public Health* 2008; 98(7): 1322-30. doi:10.2105/AJPH.2007.122192.
<https://www.ncbi.nlm.nih.gov/pubmed/18511720>
143. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. *Medscape J Med* 2008; 10(8): 190.
<https://www.ncbi.nlm.nih.gov/pubmed/18924642>
144. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. *Risk Anal* 2008; 28(4): 855-76. doi:10.1111/j.1539-6924.2008.01078.x.
<https://www.ncbi.nlm.nih.gov/pubmed/18627544>
145. Thompson KM. Reforms for rating media: disclosure, not censorship. *MedGenMed* 2007; 9(4): 27.
<https://www.ncbi.nlm.nih.gov/pubmed/18311377>
146. Lee LK, Thompson KM. Parental survey of beliefs and practices about bathing and water safety and their children: guidance for drowning prevention. *Accid Anal Prev* 2007; 39(1): 58-62. doi:10.1016/j.aap.2006.06.020. <https://www.ncbi.nlm.nih.gov/pubmed/16920055>

2001 - 2006

147. Thompson KM, Tepichin K, Haninger K. Content and ratings of mature-rated video games. *Arch Pediatr Adolesc Med* 2006; 160(4): 402-10. doi:10.1001/archpedi.160.4.402.
<https://www.ncbi.nlm.nih.gov/pubmed/16585486>
148. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal* 2006; 26(6): 1423-40. doi:10.1111/j.1539-6924.2006.00831.x.
<https://www.ncbi.nlm.nih.gov/pubmed/17184390>
149. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Caceres VM, Sangrujee N, Jafari H, Cochi SL. Development and



- consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. *Risk Anal* 2006; 26(6): 1571-80. doi:10.1111/j.1539-6924.2006.00841.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184398>
150. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. *Risk Anal* 2006; 26(6): 1541-56. doi:10.1111/j.1539-6924.2006.00843.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184396>
151. Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. *Risk Anal* 2006; 26(6): 1419-21. doi:10.1111/j.1539-6924.2006.00853.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184389>
152. Tebbens RJ, Sangruee N, Thompson KM. The costs of future polio risk management policies. *Risk Anal* 2006; 26(6): 1507-31. doi:10.1111/j.1539-6924.2006.00842.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184394>
153. Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. *Risk Anal* 2006; 26(6): 1471-505. doi:10.1111/j.1539-6924.2006.00827.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184393>
154. Talmor D, Thompson KM, Legedza AT, Nirula R. Predicting severe head injury after light motor vehicle crashes: implications for automatic crash notification systems. *Accid Anal Prev* 2006; 38(4): 767-71. doi:10.1016/j.aap.2006.01.008. <https://www.ncbi.nlm.nih.gov/pubmed/16530717>
155. Riederer AM, Thompson KM, Fuentes JM, Ford TE. Body weight and water ingestion estimates for women in two communities in the Philippines: the importance of collecting site-specific data. *Int J Hyg Environ Health* 2006; 209(1): 69-80. doi:10.1016/j.ijheh.2005.08.002. <https://www.ncbi.nlm.nih.gov/pubmed/16373204>
156. Lee LK, Mao C, Thompson KM. Demographic factors and their association with outcomes in pediatric submersion injury. *Acad Emerg Med* 2006; 13(3): 308-13. doi:10.1197/j.aem.2005.10.012. <https://www.ncbi.nlm.nih.gov/pubmed/16495427>
157. de Gourville E, Duintjer Tebbens RJ, Sangruee N, Pallansch MA, Thompson KM. Global surveillance and the value of information: the case of the global polio laboratory network. *Risk Anal* 2006; 26(6): 1557-69. doi:10.1111/j.1539-6924.2006.00845.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184397>
158. Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. *Risk Anal* 2006; 26(6): 1441-8. doi:10.1111/j.1539-6924.2006.00840.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184391>
159. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. *JAMA* 2005; 294(7): 826-32. doi:10.1001/jama.294.7.826. <https://www.ncbi.nlm.nih.gov/pubmed/16106008>
160. Thompson KM. Addicted media: substances on screen. *Child Adolesc Psychiatr Clin N Am* 2005; 14(3): 473-89, ix. doi:10.1016/j.chc.2005.02.007. <https://www.ncbi.nlm.nih.gov/pubmed/15936669>
161. Thompson KM. Kids and media: learning happens. *MedGenMed* 2005; 7(2): 47. <https://www.ncbi.nlm.nih.gov/pubmed/16369425>
162. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. *Am J Epidemiol* 2005; 162(4): 358-72. doi:10.1093/aje/kwi206. <https://www.ncbi.nlm.nih.gov/pubmed/16014773>
163. Yokota F, Gray G, Hammitt JK, Thompson KM. Tiered chemical testing: a value of information approach. *Risk Anal* 2004; 24(6): 1625-39. doi:10.1111/j.0272-4332.2004.00555.x. <https://www.ncbi.nlm.nih.gov/pubmed/15660617>
164. Thompson KM, Yokota F. Violence, sex and profanity in films: correlation of movie ratings with content. *MedGenMed* 2004; 6(3): 3. <https://www.ncbi.nlm.nih.gov/pubmed/15520625>
165. Thompson KM. Changes in children's exposure as a function of age and the relevance of age definitions for exposure and health risk assessment. *MedGenMed* 2004; 6(3): 2. <https://www.ncbi.nlm.nih.gov/pubmed/15520624>
166. Haninger K, Thompson KM. Content and ratings of teen-rated video games. *JAMA* 2004; 291(7): 856-65. doi:10.1001/jama.291.7.856. <https://www.ncbi.nlm.nih.gov/pubmed/14970065>
167. Haninger K, Ryan MS, Thompson KM. Violence in teen-rated video games. *MedGenMed* 2004; 6(1): 1. <https://www.ncbi.nlm.nih.gov/pubmed/15208514>



168. Thompson KM. The role of bath seats in unintentional infant bathtub drowning deaths. *MedGenMed* 2003; 5(1): 36. <https://www.ncbi.nlm.nih.gov/pubmed/12827097>
169. Thompson KM. How much do kids count in corporate board rooms? Results from the first survey of Fortune 1000 companies. *MedGenMed* 2003; 5(1): 37. <https://www.ncbi.nlm.nih.gov/pubmed/12827098>
170. Sangruee N, Duintjer Tebbens RJ, Caceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. *MedGenMed* 2003; 5(4): 35. <https://www.ncbi.nlm.nih.gov/pubmed/14745382>
171. Thompson KM, Segui-Gomez M, Graham JD. Validating benefit and cost estimates: the case of airbag regulation. *Risk Anal* 2002; 22(4): 803-11. doi:10.1111/0272-4332.00070. <https://www.ncbi.nlm.nih.gov/pubmed/12224752>
172. Thompson KM, Haninger K. Violence in E-rated video games. *JAMA* 2001; 286(5): 591-8. doi:10.1001/jama.286.5.591. <https://www.ncbi.nlm.nih.gov/pubmed/11476663>
173. Juberg DR, Alfano K, Coughlin RJ, Thompson KM. An observational study of object mouthing behavior by young children. *Pediatrics* 2001; 107(1): 135-42. doi:10.1542/peds.107.1.135. <https://www.ncbi.nlm.nih.gov/pubmed/11134447>

1991 - 2001

174. Yokota F, Thompson KM. Violence in G-rated animated films. *JAMA* 2000; 283(20): 2716-20. doi:10.1001/jama.283.20.2716. <https://www.ncbi.nlm.nih.gov/pubmed/10819958>
175. Thompson KM, Segui-Gomez M, Graham JD. Validating analytical judgments: the case of the airbag's lifesaving effectiveness. *Reliability Engineering & System Safety* 1999; 66(1): 57-68. doi:10.1016/S0951-8320(99)00019-8. <https://www.sciencedirect.com/science/article/pii/S0951832099000198>
176. Graham JD, Goldie SJ, Segui-Gomez M, Thompson KM, Nelson T, Glass R, Simpson A, Woerner LG. Reducing risks to children in vehicles with passenger airbags. *Pediatrics* 1998; 102(1): e3. doi:10.1542/peds.102.1.e3. <https://www.ncbi.nlm.nih.gov/pubmed/9651455>
177. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of air bags by seating position. *JAMA* 1997; 278(17): 1418-25. doi:10.1001/jama.1997.03550170048031. <https://www.ncbi.nlm.nih.gov/pubmed/9356000>
178. Thompson KM, Burmaster DE. Parametric distributions for soil ingestion by children. *Risk Anal* 1991; 11(2): 339-42. doi:10.1111/j.1539-6924.1991.tb00610.x. <https://www.ncbi.nlm.nih.gov/pubmed/1876729>